Library

Notes: Dr. Dorros: Our next speaker has evolved from a cardiovascular surgeon doing vascular surgery to a cardiovascular surgeon performing endovascular therapy of bifurcation disease. We have asked Dr. Diethrich from the Arizona Heart Institute to give us a cardiovascular surgeon's perspective.

Notes: Abstract  Advances in endoluminal technology have enabled interventionists to treat a variety of pathologies that traditionally would require open surgery. Although excluding descending thoracic aortic aneurysms seems feasible, thoracic aortic dissection and its complications are an area in which the appropriateness of endovascular therapy has yet to be defined. Five case reports are presented, each with varying pathologies associated with type III dissections. The follow-up of the cases ranged from 6 to 18 months with a mean of 12.2 months. The endovascular approach and the technical aspect of the intervention have been emphasized in each case. (J Card Surg 2003; 18:334-350)

Notes: Abstract  Background: Thoracic aortic dissections, ruptures, fistulae, and aneurysms pose a unique surgical challenge. Traditional repair of thoracic aortic aneurysms involves thoracotomy with graft interposition. Despite advances in perioperative care and both total and partial cardiopulmonary bypass, conventional surgery carries a significant morbidity and mortality. Principal complications include bleeding, paraplegia, stroke, cardiac events, pulmonary insufficiency, and renal failure. Recent enthusiasm for innovative endovascular therapies to treat aortic disease has spurred many centers to investigate endoluminal grafting of the thoracic aorta. Early reports on endovascular repair using custom made “first generation devices” demonstrated the technique to be feasible with a mortality and morbidity comparable to open repair. Methods and results: From February 2000 to February 2001, endovascular stent graft repair of the thoracic aorta was performed in 46 patients (mean age 70; 29 male and 17 female) using the Gore Excluder. Twenty-three patients (50%) had atherosclerotic aneurysms, fourteen patients (30%) had dissections, three patients (7%) had aortobronochial fistulas, three patients (7%) had pseudoaneurysms, two patients (4%) had traumatic ruptures, and one patient (2%) had a ruptured aortic ulcer. Patient characteristics, procedural variables, outcomes, and complications were recorded. All patients were followed with chest CT scans at 1, 3, 6, and 12 months. Mean follow up was 9 months ranging from 1 to 15 months. All procedures were technically successful. There were no conversions. Average duration of the procedure was 120 minutes. Average length of stay was 6 days, but most patients left the hospital within 4 days (64%) after endoluminal grafting. Overall morbidity was 23%. Two patients (4%) had endoleaks that required a second procedure for successful repair. Two patients (4%) died in the immediate postoperative period. There were no cases of paraplegia. At follow-up, one patient had an endoleak found the day after the procedure and another patient had an endoleak 6 moths post procedure. Both were treated successfully with additional stent grafts. There were no cases of migration. One patient died of a myocardial infarction 6 months after graft placement. The Gore Excluder device was voluntarily recalled on February 26, 2001. Therefore, from June 2000 to January 2001, 37 patients underwent endovascular stent graft repair of the thoracic aorta for various disease entities using our customized thoracic graft (Endomed). Twenty-seven patients (73%) had aneurysms, six (16%) had dissections, two (5%) had pseudoaneurysms, one (2%) had a traumatic transection, and one patient (2%) had an embolizing ulcer. Patients were followed with CT scans at 1, 3, 6, and 12 months. All procedures were technically successful. There were no conversions. The average age was 68 years.(17–87). And the male and female ratio was 24/13. One patient died in the operating room from iliac rupture and one died from embolization/stroke in the immediate postoperative period. Two patients died within 30 days from comorbid factors. The total 30-day mortality was 10%. Two patients had endoleaks. One returned to the operating room and needed an additional cuff. The other had a small leak in a proximal dissection that is being followed. There were no cases of paraplegia. Conclusion: Thoracic endoluminal grafting is a safe and feasible alternative to open graft repair and can be performed successfully with good results. Early data suggest that an endoluminal approach to these disease entities maybe favorable to open resection and graft replacement. Technical details of Endoluminal stent grafting of the thoracic aorta for different disease entities have been discussed at length.

Notes: The proliferation of sophisticated endovascular interventions is mandating more definitive and comprehensive documentation of atherosclerotic lesions and the results of the interventional devices used in their removal. A technique with a potential to fulfill these goals, intravascular ultrasound imaging (IVUS), was evaluated against pressure gradients, arteriography, and femoral-radial indices in 11 patients with stenotic iliac lesions. The two-dimensional, real-time scans were useful in measuring pre-and posttreatment cross-sectional diameters and luminal areas for procedural assessment. Furthermore, the ultrasound scans clearly identified arterial wall calcifications, iliac veins, soft plague formations, dissections, synthetic graft anastomoses, and intravascular stents, often with definition superior to arteriography. The IVUS technique was useful in selecting interventional therapies, in particular, the need for stent implantation to control intimal flaps. Further, IVUS demonstrated its ability as a substitute for contrast arteriography in a twelfth patient with an iliac stent in whom a protocol-dictated follow-up arteriogram was contraindicated.

Notes: Endovascular interventions were developed to provide minimally invasive alternatives to standard surgical therapies. Where an endoluminal technique has the potential to supplant its surgical predecessor, the rival must prove itself against the gold standard in terms of outcome, complications, and durability. In the case of carotid stenting, the stroke risk reduction data for carotid endarterectomy gathered from recent randomized trials appear to be unassailable. In the face of this challenge, why would we pursue an endoluminal alternative? Would the investment in resources and device development result in benefit to the patient? In this perspective, an endovascular surgeon proposes several possible case scenarios appropriate to carotid stenting and reviews progress to date on the investigation of this therapeutic alternative.

Notes: While carotid endarterectomy (CEA) has been used commonly and with great effectiveness for de novo carotid occlusive lesions, its success in cases of recurrent disease has been attenuated by a higher incidence of complications and lower durability. Although interventional techniques have been introduced cautiously into the cerebrovascular system, balloon dilation for both primacy and recurrent carotid atherosclerotic disease has been successful in establishing an adequate lumen without an increase in embolic complications over surgery. Because the likelihood exists that postdilation restenosis may be as common in the carotid arteries as it is in other vascular segments, the use of intraluminal stenting may mitigate this long-term complication, a benefit that has been demonstrated in other high flow vessels such as the aorta and iliac arteries. To begin an investigation of this hypothesis, we treated a 69-year-old symptomatic man who required a third intervention for recurrent carotid disease. A 〉 90% stenosis of the distal third of his right common carotid artery was successsfully dilated, and a Palmaz stent was deployed without incident. The patient experienced no complicatons to the percutaneous procedure, and at 15 months posttreatment, he is well and asymptomatic. Although greater clinical experience must be accumulated with this new approach, intraluminal stenting following balloon dilation for recurrent carotid disease may surpass redo CEA in long-term patency and may entail fewer procedural complications. (J Interven Cardiol 1995; 8:213–218)

Notes: [Auszug] Prior treatment of human allograft recipients with aggregate-free normal horse immunoglobulin circumvents the problem of antibody formation in subsequent anti-lymphocytic globulin ...

Notes: Abstract For more than 40 years, endarterectomy and bypass grafting have been the primary means of surgically revascularizing peripheral vessels threatened by atherosclerotic disease. However, with today's endovascular technology, stenoses and occlusions in nearly every circulatory system can be approached intraluminally with a wide variety of techniques: thrombolysis, laser angioplasty, atherectomy, balloon dilation, and intravascular stents. Just as exciting is the newer technique of endoluminal grafting, which has extended percutaneous therapy to aneurysmal disease in the thoracic and abdominal aorta and distal arteries, as well as to long-segment occlusive disease. Today's vascular surgeon is in a unique position to combine his or her classical surgical training with these catheter-based interventions. Certainly, the potential advantages of percutaneous therapy as compared to surgical reconstruction are significant: no general anesthesia or lengthy incisions, shorter hospitalization, lower morbidity and mortality, earlier intervention in the course of the disease, and less complicated reapplication in the event of disease recurrence. Undoubtedly, endovascular techniques will become a major component of the vascular surgeon's armamentarium, and as we approach the year 2000, they will be the treatment of choice in nearly every vascular pathology and circulatory system.